Kähler, Katharina C.
Hüning, S.
Nashan, D.
Meiss, F.
Rafei-Shamsabadi, D. A.
Rissmann, H.
Colapietro, C.
Livingstone, E.
Maul, L. V.
Heppt, M.
Hassel, J. C.
Gutzmer, R.
Loquai, C.
Heinzerling, L.
Sachse, M. M.
Bohne, A. S.
Moysig, L.
Peters, W.
Rusch, J.
Blome, C.
Funding for this research was provided by:
Novartis
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Article History
Received: 31 May 2023
Accepted: 26 June 2023
First Online: 5 July 2023
Declarations
:
: Dr Kähler serves as consultant to Philogen, BMS, MSD, Sanofi Aventis, Immunocore and received travel grants and speaker fees from Philogen, Pierre Fabre, BMS, MSD, Sun Pharma, Sanofi Aventis, Novartis, Medac and has received research support by Novartis. Dr Hüning has received travel support or/and speaker’s fees or/and advisor’s honoraria by BMS, Kyowa Kirin, MSD, Pierre Fabre, Sun Pharma. Dr Nashan has no conflicts. Dr Meiss declares speaker and advisory board honoraria from Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Sanofi Genzyme, Sun Pharma and travel support from Novartis, Sun Pharma, Roche, Pierre Fabre and Merck Sharp & Dohme. Dr Rafei-Shamsabadi served as consultant and/or has received honoraria from Roche and BMS and travel support from Sunpharma and Sanofi. Mr Rissmann has no conflicts. Mrs Colapietro has no conflicts. Dr Livingstone received honoraria from Novartis, Medac, Bristol Myers Squibb, Sanofi, Sun Pharma, and Pierre Fabre, reports consulting/advisory roles with Bristol Myers Squibb, Pierre Fabre and Novartis; and received travel/accommodations/expenses from Pierre Fabre, Bristol Myers Squibb, Medac, and Sun Pharma. Dr Maul has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Almirall, Amgen, BMS, Celgene, Eli Lilly, MSD, Novartis, Pierre Fabre, Roche and Sanofi. Dr Heppt received honoraria from Honoraria from MSD, BMS, Roche, Novartis, Sun Pharma, Sanofi, Almirall, Biofrontera, Galderma. Dr Hassel serves as consultant for GSK, MSD, Pierre Fabre, Sunpharma, Onkowissen, received speaker honoraris from Amgen, BMS, GSK, Immunocore, Novartis, Pierre Fabre, Sanofi, Sunpharma and travel support by BMS, Iovance and Sunpharma. Dr Gutzmer received research support from Novartis, SUN, Amgen, Sanofi, Merck-Serono, Kyowa-Kirin, Almirall-Hermal (to institution), honoraria for lectures and advice from Roche Pharma, Bristol-MyersSquibb, Novartis, MSD, Almirall-Hermal, Amgen, Merck-Serono, SUN, Pierre-Fabre, Sanofi, 4SC, Sanofi, Immunocore (to person) and travel/meeting support from Pierre Fabre, SUN and Boehringer Ingelheim (to person). Dr Loquai received Dr Loquai received speaker’s fee, advisory board and travel reimbursement: Merck, MSD, Roche, Almirall Hermal, Biontech, Sanofi, Sun Pharma, Kyowa Kirin, Immonocore, BMS, Pierre Fabre, Novartis. Dr Heinzerling Lucie Heinzerling declares speakers and advisory board honoraria from: Amgen. Bristol Myers Squibb, CureVac AG, Kyowa Kirin, Merck Sharp & Dohme GmbH, Novartis Pharma GmbH, Pierre Fabre Pharma GmbH, Roche, Sanofi-Aventis Deutschland GmbH, SUN Pharmaceuticals Germany GmbH, Therakos. Dr Sachse received speaker fees from Roche, MSD, Novartis. Dr Bohne has received travel grants from Sun Pharma, Pierre-Fabre and Bristol-Myers Squibb outside the submitted work. Mrs Moysig has no conflicts. Mrs Peters has no conflicts. Ms Rusch has no conflicts. Dr Blome has received speaker honoraria, research grants and/or awards from Amgen/Celgene, AstraZeneca, Bauerfeind, Hartmann, Helios Klinik Leisnig, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Pfizer, Stiefel Laboratories, The EuroQol Group, and Urgo.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Christian-Albrechts-University Kiel (2nd March 2020/D435/20).
: All patients have given written informed consent.